Biostage Inc. (BSTG)

0.23  -0.07 (-23.33%)

After market: 0.25 +0.02 (+8.7%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

Biostage Inc.

NASDAQ:BSTG (10/5/2017, 7:10:00 PM)

After market: 0.25 +0.02 (+8.7%)

0.23

-0.07 (-23.33%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap8.98M
Shares
PEN/A
Fwd PEN/A
Dividend Yield0%
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

BSTG Daily chart

Company Profile

Biostage, Inc. is a biotechnology company. It is engaged in developing bioengineered organ implants based on the company's new Cellframe (TM) technology to treat life-threatening conditions of the esophagus, trachea or bronchus. Biostage Inc., formerly known as Harvard Apparatus Regenerative Technology Inc., is based in HOLLISTON, Mass.

Company Info

Biostage Inc.

84 October Hill Road Suite 11

Holliston MA 01746

P: 774-233-7300

CEO: James McGorry

BSTG News

News Imagea year ago - Biostage, Inc.Biostage to Host Investor Call

/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing the technology to regenerate...

News Imagea year ago - Biostage, Inc.Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease

HOLLISTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a clinical-stage biotechnology company...

News Imagea year ago - Biostage, Inc.Biostage Appoints Ron Packard to Board of Directors

HOLLISTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company...

News Imagea year ago - Biostage, Inc.Biostage Announces $6 Million Financing to Advance Clinical Trial

HOLLISTON, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company...

News Imagea year ago - Biostage, Inc.Biostage Announces Chairman and CEO Transition

/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing regenerative-medicine treatments...

News Imagea year ago - Seeking AlphaRegenerative medicine developer Biostage scraps Nasdaq uplisting, offering

Regenerative medicine developer Biostage (BSTG) has scrapped plans for an uplisting and accompanying public offering. Read more here.

BSTG Twits

Here you can normally see the latest stock twits on BSTG, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example